Halozyme Therapeutics Stock News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno

Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wal

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.82 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.48 per share a year ago.

Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as compa

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.